==== Front Sci Rep Sci Rep Scientific Reports 2045-2322 Nature Publishing Group UK London 78205 10.1038/s41598-020-78205-5 Article Clinical and molecular analysis in a cohort of Chinese children with Cornelia de Lange syndrome Li Qun 1 Chang Guoying 1 Yin Lei 2 Li Juan 1 Huang Xiaodong 1 Shen Yongnian 1 Li Guoqiang 3 Xu Yufei 3 Wang Jian labwangjian@shsmu.edu.cn 3 Wang Xiumin wangxiumin1019@126.com 1 1 grid.16821.3c0000 0004 0368 8293Department of Endocrinology and Metabolism, Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine, 1678 Dongfang Road, Shanghai, 200127 China 2 grid.16821.3c0000 0004 0368 8293Department of Rare Disease Clinic, Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China 3 grid.16821.3c0000 0004 0368 8293Department of Medical Genetics and Molecular Diagnostic Laboratory, Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China 4 12 2020 4 12 2020 2020 10 212245 1 2020 9 11 2020 © The Author(s) 2020Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Cornelia de Lange Syndrome (CdLS) is a rare genetic disorder, which causes a range of physical, cognitive, and medical challenges. To retrospectively analyze the clinical characteristics and genetic variations of Chinese patients, and to provide experience for further diagnosis and treatment of CdLS in Chinese children, we identified 15 unrelated Chinese children who presented with unusual facial features, short stature, developmental delay, limb abnormalities, and a wide range of health conditions. In this study, targeted-next generation sequencing was used to screen for causal variants and the clinically relevant variants were subsequently verified using Sanger sequencing. DNA sequencing identified 15 genetic variations, including 11 NIPBL gene variants, two SMC1A gene variants, one RAD21 gene variant, and one HDAC8 variant. The phenotype of these patients was summarized and differences between this cohort and another four groups were compared. The clinical manifestations of the patients in this cohort were mostly consistent with other ethnicities, but several clinical features in our cohort had different frequencies compared with other groups. We identified 15 deleterious variants of which 11 were novel. Variants in the NIPBL gene were the most common cause in our cohort. Our study not only expands upon the spectrum of genetic variations in CdLS, but also broadens our understanding of the clinical features of CdLS. Subject terms DiseasesGenotypeJin Lei Pediatric Endocrinology Growth Research Fund for Young PhysiciansNo. PEGRF201809007Li Qun National Natural Science Foundation of ChinaNo. 81900722Chang Guoying issue-copyright-statement© The Author(s) 2020 ==== Body Introduction Cornelia de Lange syndrome (CdLS, OMIM#122470, 300590, 300882, 610759, and 614701), which is also called Brachmann de Lange syndrome, is a multiple congenital anomaly syndrome characterized by typical facial features, growth impairment and intellectual disability, limb reduction defects, and involvement of other systems1. The prevalence of CdLS is estimated to be between 1 in 10,000 and 1 in 30,000 live births2. Although most cases of CdLS are dominant and sporadic, recurrence in siblings due to parental mosaicism has been reported3. Genetic variations leading to CdLS have been identified in the following seven genes: NIPBL, SMC1A, SMC3, RAD21, BRD4, HDAC8, and ANKRD112. Among these genes, NIPBL is a cohesion loading factor. SMC1A, SMC3, and RAD21 code for structural components of the cohesin complex. HDAC8 codes for an SMC3 deacetylase that is involved in cohesin recycling. Cohesin proteins are involved in regulating chromosome segregation, gene expression, DNA repair, and maintenance of genome stability4. Genotype–phenotype correlations have shown that NIPBL variants usually result in more severe phenotype than variants in other genes5. In addition, other genes were described in patients presenting features of CdLS or CdLS-like phenotype as well (i.e. EP300, AFF4)2. In order to explore the clinical phenotype spectrum and gene spectrum of Chinese CdLS, we retrospectively analyze the clinical characteristics and genetic variations of our patients. In this study, we analyse the clinical features and the results of genetic testing of 15 patients who were diagnosed with CdLS. All of the patients harbored variants in NIPBL, SMC1A, RAD21, or HDAC8, of which 11 variants were novel. The phenotype of these Chinese patients was compared with four other groups. Materials and methods Patients A total of 15 affected and unrelated children from Chinese families who were referred to Shanghai Children’s Medical Center were included in the study. Detailed medical history was recorded by pediatricians. Their clinical data were collected, such as sex, age, birth history, family history, clinical symptoms, craniofacial features, limb features, height, and weight, and laboratory examinations were performed. The preliminary diagnosis of CdLS was made by pediatricians and based on clinical manifestations and laboratory examinations according to the Diagnostic Criteria for Cornelia de Lange Syndrome by Antonie D. Kline (2007)1 and the clinical diagnostic criteria by the first international consensus statement (2018)2. Informed consent for the genetic analysis was obtained from the patients’ parents. This study was approved by the Ethics Committee of Shanghai Children’s Medical Center. All methods were performed in accordance with the relevant guidelines and regulations [International Ethical Guidelines for Health-related Research Involving Humans, Fourth Edition. Geneva. Council for International Organizations of Medical Sciences (CIOMS); 2016]. Targeted next-generation sequencing and data analysis Targeted next-generation sequencing (NGS) was performed as described in our previous study6. Briefly, both coding exons and flanking intronic regions were enriched using an XT Inherited Disease Panel (cat No.5190-7519, Agilent technologies Inc., Santa Clara, CA, USA) consisting of 2742 genes. BRD4 and the other genes involved in CdLS-like phenotype are not included in this panel. Sequencing was performed on an Illumina HiSeq 2500 System (Illumina, San Diego, CA, USA). Alignment of the sequence reads to a reference human genome (Human 37.3; SNP135) was performed using NextGENe (SoftGenetics, State College, PA, USA). All single nucleotide variants (SNVs) were saved in a VCF format file and uploaded to Ingenuity Variant Analysis (Ingenuity Systems, Redwood City, CA, USA) for biological analysis and interpretation. The variants detected by NGS were validated by Sanger sequencing in the patients and their parents if the samples were available. According to the variant-interpretation guidelines from the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology7, which was evolved by ClinGen Sequence Variant Interpretation Working Group (https://www.clinicalgenome.org/working-groups/sequence-variant-interpretation/)8,9, we categorized the pathogenicity of variants. Statistics analysis Statistical analysis for comparison between our cohort and four other groups was performed by (corrected) the chi-square test or Fisher’s exact test using SPSS 22.0 software. P values were adjusted by pairwise comparison using the Bonferroni test. P < 0.05 was considered statistically significant. Ethical approval The Ethics Committee of Shanghai Children’s Medical Center approved the study (SCMCIRB-W2019014, 19 September 2019). Results Gene variants A CdLS-related gene variant was found in all of the 15 patients, 14 were diagnosed by genetic testing in our hospital and one case was tested in another hospital and referred to our hospital for genetic counseling (Table 1). Among the 15 patients, 11 NIPBL gene variants (11/15, 73.3%; 4 splicing, 3 missense, 2 frameshift, and 2 nonsense variants), two SMC1A gene missense variants (2/15, 13.3%), one RAD21 gene frameshift variant (1/15, 6.7%), and one HDAC8 gene splicing variant (1/15, 6.7%) were detected. Of the 15 identified variants, 11 were novel, and p. (Cys781Phe) in SMC1A and c.6763 + 5G > T, c.7264-6 T > G, and c.-79-2A > G in NIPBL have been reported previously10–13. Except for patient 8 (P8) whose parents’ samples were not available and P14 whose mother’s sample was not available, the mother of P12 carried the same variant and the other 12 patients had de novo variants (Fig. 1). According to ACMG guidelines, 15 gene variants were classified, among which seven were pathogenic and eight were likely pathogenic (Supplementary Table S1).Table 1 Variants identified in our patients. Case Variants Location Type Homo/Het Inherited or De novo Novel or reported ACMG classification 1 NIPBL(NM_133433.3) : c.6109-1G > A Intron 34 Splicing Het De novo Novel P 2 NIPBL (NM_133433.3) : c.6763 + 5G > T Intro 39 Splicing Het De novo Reported P 3 NIPBL (NM_133433.3) : c.7264-6T > G Intron 42 Splicing Het De novo Reported LP 4 NIPBL(NM_133433.3) : c.-79-2A > G 5′UTR regions Splicing Het De novo Reported LP 5 NIPBL (NM_133433.3) : c.5683A > G, p. (Arg1895Gly) Exon 30 Missense Het De novo Novel P 6 NIPBL (NM_133433.3) : c.5615T > A, p. (Leu1872His) Exon 30 Missense Het De novo Novel LP 7 NIPBL(NM_133433.3) : c. 6722T > C, p. (Leu2241Pro) Exon 39 Missense Het De novo Novel LP 8 NIPBL(NM_133433.3) : c.6854_6855delAG, p. (Gln2285Argfs*3) Exon 40 Frameshift Het NA Novel LP 9 NIPBL (NM_133433.3) : c.330_331delAA, p. (Ser111Hisfs*16) Exon 4 Frameshift Het De novo Novel P 10 NIPBL(NM_133433.3) : c.3344G > A, p. (Trp1115*) Exon 12 Nonsense Het De novo Novel P 11 NIPBL (NM_133433.3) : c.4310 T > G, p. (Leu1437*) Exon 19 Nonsense Het De novo Novel P 12 SMC1A (NM_006306.2) : c.2342G > A, p. (Cys781Phe) Exon 15 Missense Hemizygote Mother reported LP 13 SMC1A(NM_006306.2) : c.1088G > T, p. (Arg363Ile) Exon 6 Missense Hemizygote De novo Novel LP 14 RAD21 (NM_006265.2) : c.1553_1554delAG, p. (Glu518Valfs*18) Exon 12 Frameshift Het NA Novel LP 15 HDAC8(NM_018486.2) : c.628 + 1G > C Intron 6 Splicing Het De novo Novel P Homo homozygosis, Het heterozygosis, NA not available, LP likely pathogenic, P pathogenic. Figure 1 Variants identified in the P1-6 (a–f) and P8-15 (g–n). Clinical manifestations A total of 15 patients were included in the study, including nine (60.0%) boys and six (40.0%) girls. The patients ranged in age from 3 months to 10 years and 2 months, with a median age of 4 years. They underwent a comprehensive clinical evaluation. Detailed data of the evaluation are shown in supplementary Table S2. The patients were scored using clinical diagnostic criteria2 and 10 (66.7%) scored > 11 points. Among the typical facial features of CdLS, except for P15, the other 14 patients showed long eyelashes. Thirteen patients had thick eyebrows and arched eyebrows except P14 and P15. Additionally, microcephaly (93.3%), anteverted nares (73.3%), long and smooth philtrum (73.3%), downturned corners of mouth (80.0%), high palate (80.0%), and micrognathia (73.3%) also appeared with high frequency in our cohort. Facial features and clinical characteristics of our CdLS patients are listed in Table 2. According to evaluation of growth and development, eight (53.3%) patients had intrauterine growth retardation, 14 (93.3%) showed short stature, and 14 (93.3%) had developmental delay. Skeletal malformations were mainly mild limb abnormalities, including small hands (73.3%) and 5th finger clinodactyly or short 5th finger (66.7%). A single transverse palmar crease (40.0%), 2–3 toe syndactyly (13.3%), and pectus excavatum (13.3%) were also observed. Severe limb deformity was found in only one patient (oligodactyly, 6.7%). In this cohort, the frequencies of male cryptorchidism, congenital heart disease (CHD), and renal abnormalities were 55.6%, 46.7%, and 13.3%, respectively. A total of 20.0% of patients had hearing abnormalities and 13.3% had otitis media. One patient (P2) had bilateral sensorineural deafness and received cochlear implantation at the age of 9 months. A total of 26.7% of the patients had a history of vomiting and feeding difficulty in infancy.Table 2 Selected clinical data in our cohort of 15 patients with CdLS (n = 15). Clinical findings N/Total(%) of subjects Total NIPBL (11) SMC1A (2) RAD21 (1) HDAC8 (1) Craniofacial features Microcephaly 14 (93.3%) 11 2 0 1 Synophrys 8 (53.3%) 7 1 0 0 Highly arched eyebrow; thick eyebrow 13 (86.7%) 11 2 0 0 Long eyelashes 14 (93.3%) 11 2 1 0 Concave nasal ridge 10 (66.7%) 9 1 0 0 Anteverted nares 11 (73.3%) 10 1 0 0 Short nose 9 (60.0%) 9 0 0 0 Long philtrum; smooth philtrum 11 (73.3%) 10 1 0 0 Thin upper lip vermilion 10 (66.7%) 9 1 0 0 Downturned corners of mouth 12 (80.0%) 11 1 0 0 High palate 12 (80.0%) 9 1 1 1 Cleft palate 2 (13.3%) 1 1 0 0 Widely spaced teeth 2 (13.3%) 2 0 0 0 Micrognathia 11 (73.3%) 10 1 0 0 Ptosis 5 (33.3%) 5 0 0 0 Growth abnormality Intrauterine growth retardation 8 (53.3%) 7 1 0 0 Short stature 14 (93.3%) 11 1 1 1 Global developmental delay; intellectual disability 14 (93.3%) 10 2 1 1 Musculoskeletal Oligodactyly 1 (6.7%) 1 0 0 0 Small hand 11 (73.3%) 9 1 1 0 5th finger clinodactyly; short 5th finger 10 (66.7%) 8 0 1 1 2–3 toe syndactyly 2 (13.3%) 2 0 0 0 Single transverse palmar crease 6 (40.0%) 5 1 0 0 Pectus excavatum 2 (13.3%) 2 0 0 0 Hypertrichosis 3 (20.0%) 3 0 0 0 Neurology Seizures 1 (6.7%) 1 0 0 0 Abnormal muscle tone 1 (6.7%) 0 1 0 0 Sensory system Hearing impairment 3 (20.0%) 3 0 0 0 Otitis media 2 (13.3%) 2 0 0 0 Malformation of the heart and great vessels 7 (46.7%) 5 2 0 0 Atrial septal defect 3 (20.0%) 2 1 0 0 Pulmonic stenosis 3 (20.0%) 2 1 0 0 Ventricular septal defect 1 (6.7%) 1 0 0 0 Coronary-pulmonary artery fistula 1 (6.7%) 1 0 0 0 Patent ductus arteriosus 1 (6.7%) 1 0 0 0 Patent foramen ovale 1 (6.7%) 0 1 0 0 Abnormality of the genitourinary system 7 (46.7%) 6 1 0 0 Abnormality of kidney 2 (13.3%) 2 0 0 0 Cryptorchidism 5/9 (55.6%) 4 1 0 0 Micropenis 2/9 (22.2%) 2 0 0 0 Hypospadias 2/9 (22.2%) 2 0 0 0 Feeding difficulties; vomiting 4 (26.7%) 4 0 0 0 Interestingly, one patient (P10) was diagnosed with growth hormone (GH) deficiency in a local hospital. With treatment of GH, his blood glucose was as high as 43.16 mmol/L. GH treatment was then ceased and insulin treatment was instituted. After 1-week therapy, the patient received metformin treatment, and his blood glucose level was normal. Phenotypic comparison of our Chinese cohort with another four groups For further understand CdLS, we did statistical analysis for the phenotype features between our cohort and a large cohort of four other groups (African and African American, Asian, Latin American, and the Middle East)14. As shown in Table 3, several features showed significant statistical difference in the cohorts. We found that the frequencies of synophrys, long eyelashes, short nose/anteverted nares, long philtrum, ptosis, palate anomalies, hypertrichosis, and hearing loss were significantly different among the cohorts (P values were < 0.001, 0.014, 0.028, 0.004, 0.018, 0.038, 0.001, and 0.004, respectively.). Further analysis showed that our cohort had a lower frequency of synophrys than did the African group and Latin American group. The frequency of palate anomalies in the Middle East group was higher than that in our cohort. Our cohort had a lower frequency of hypertrichosis than did the African group, Latin American group, and Middle East group. The frequency of hearing loss in the African group was higher than that in our cohort (Table 3).Table 3 Clinical features of our cohort compared with four other groups. Our study n = 15 Africa n = 14 Asia n = 23 Latin America n = 22 Middle East n = 8 Chi-square value p-Values Average age (years) 4 1.4 4.3 6.5 2.6 Age range 3m–10y2m 2w–9y 2w–12y 1d–37y 3m–8y NIPBL (%) 11/15 (73%) 6/6 (100%) 6/8 (75%) 77% 3/5 (60%) HDAC8 (%) 1/15 (7%) 0 2/8 (25%) 18% 1/5 (20%) SMC1A (%) 2/15 (13%) 0 0 5% 1/5 (20%) RAD21(%) 1/15 (7%) 0 0 0 0 Synophrys 8/15 (53.3%) 14/14 (100.0%)a 21/23 (91.3%) 22/22 (100.0%)a 7/8 (87.5%) 16.357 < 0.001 Arched eyebrows 13/15 (86.7%) 14/14 (100.0%) 21/23 (91.3%) 22/22 (100.0%) 8/8 (100.0%) 4.058 0.286 Long eyeashes 14/15 (93.3%) 14/14 (100.0%) 23/23 (100.0%) 22/22 (100.0%) 6/8 (75.0%) 7.486 0.014 Short nose/anteverted nares 11/15 (73.3%) 14/14 (100.0%) 19/23 (82.6%) 22/22 (100.0%) 7/8 (87.5%) 8.738 0.028 Long philtrum 11/15 (73.3%) 14/14 (100.0%) 23/23 (100.0%) 22/22 (100.0%) 8/8 (100.0%) 9.995 0.004 Ptosis 5/15 (33.3%) 10/14 (71.4%) 9/23 (39.1%) 8/22 (36.4%) 0/8 (0.0%) 11.612 0.018 Palate anomalies 2/15 (13.3%) 3/13 (23.1%) 2/18 (11.1%) 6/22 (27.3%) 4/5 (80.0%)a 9.447 0.038 Micrognathia 11/15 (73.3%) 11/13 (84.6%) 10/18 (55.6%) 13/22 (59.1%) 2/5 (40.0%) 5.011 0.285 Clinodactyly 10/15 (66.7%) 12/13 (92.3%) 10/18 (55.6%) 10/22 (45.5%) 3/5 (60.0%) 8.472 0.068 Hypertrichosis 3/15 (20.0%) 11/13 (84.6%)a 12/18 (66.7%) 15/22 (68.2%)a 5/5 (100.0%)a 16.713 0.001 Growth deficiency 14/15 (93.3%) 13/13 (100.0%) 18/18 (100.0%) 22/22 (100.0%) 4/5 (80.0%) 5.688 0.057 Hearing loss 1/15 (6.7%) 9/13 (69.2%)a 4/18 (22.2%) 7/22 (31.8%) 3/5 (60.0%) 14.644 0.004 Congenital heart disease 7/15 (46.7%) 3/13 (23.1%) 4/18 (22.2%) 9/22 (40.9%) 2/5 (40.0%) 3.478 0.500 Renal anomalies 2/15 (13.3%) 4/13 (30.8%) 2/18 (11.1%) 2/22 (9.1%) 1/5 (20.0%) 3.482 0.465 Neurologic abnormalities 2/15 (13.3%) 1/13 (7.7%) 1/18 (5.6%) 1/22 (4.5%) 0/5 (0.0%) 1.732 0.902 aIndicates that the incidence of phenotype was statistically significant compared with our cohort. The four other groups (African and African American, Asian, Latin American, and the Middle East) of features data were from the Dowsett et al.14. Discussion There is a wide range of severity of clinical characteristics observed in patients with CdLS, including typical facial features, growth retardation, intellectual disability, limb defects, and involvement of other systems. These features widely vary among affected patients and range from relatively mild to severe. Facial features (synophrys, thick eyebrows and arched eyebrows, long eyelashes, anteverted nares, long and smooth philtrum, thin lips, downturned corners of the mouth, etc.) are the most clinically consistent and recognizable findings in CdLS, which suggest this syndrome in the clinic15. In our cohort, 11 patients (P1 ~ P11) had NIPBL variants, of which, 9 of these patients were diagnosed with classic CdLS (scoring > 11 points), all of them showed these facial features. The patients (P13, P14, P15) with lower score (4 points) with SMC1A, RAD21 and HDAC8 variants had only few facial features of with CdLS. Furthermore, P15 had hypertelorism and a broad nasal tip, which is consistent with other reported patients with HDAC8 variants16. In our study, most patients were referred for the chief complaint of growth retardation and developmental delay, which are the common features of most CdLS patients. Based on the assessment of growth and development, fourteen (93.3%) patients had developmental delay, 53.3% of the patients had intrauterine growth retardation and 93.3% of the patients showed short stature (60.0% of these patients had a height below—3SD). Skeletal anomalies ranged from small hands to more severe reduction defects of the fingers. Small hands and 5th finger clinodactyly were the most common anomalies in all of our patients. Additionally, a single transverse palmar crease, 2–3 toe syndactyly, and pectus excavatum were observed in our patients. Other system disorders are also involved in CdLS. Feeding problems are typical in infancy in CdLS. In our cohort, four (26.7%) patients had feeding difficulties and vomiting. The incidence of CHD in CdLS is reported to approximately 14–70%, and the most common CHDs are pulmonic and peripheral pulmonic stenosis, followed by ventricular septal defect and atrial septal defect17. In our cohort, the incidence of CHD was 46.7%, with mainly pulmonic stenosis and atrial septal defect. Cryptorchidism was commonly found in our male patients. Interestingly, hyperglycemia was also observed in one patient (P10). Type 2 diabetes mellitus develops in 4% of individuals in adulthood18. However, there is no clear evidence of an increased risk of diabetes in children with CdLS, and no other similar cases have been published. Therefore, hyperglycemia probably occurred with CdLS in our patient by chance. Several features (synophrys, palate anomalies, hypertrichosis, and hearing loss) in our cohort were significantly different from four other groups (African and African American, Asian, Latin American, and the Middle East14). We speculate that the low incidence of synophrys and hypertrichosis in our cohort compared with other groups may be a result of ethnic differences in hair density. With regard to involvement of other systems, CHD, renal anomalies, and neurological abnormalities were not significantly different between our cohort and four other groups. Hearing loss had a lower frequency in our cohort than in the African group which may be due to the different gene variation types. In the African group, all patients had NIPBL gene variants. In the future, we hope to enroll more cases in order to evaluate the differences between phenotypic findings between our cohort and other cohorts. CdLS is characterized by a wide genetic heterogeneity and caused by cohesin complex-associated genetic variants. The most commonly known genetic cause of CdLS is NIPBL gene variants, which can be identified in approximately 70% of cases2. The NIPBL gene is located on chromosome 5p13.2, and it spans more than 190 kb and contains 47 exons. To date, more than 300 different NIPBL variants have been reported in patients with CdLS, including missense/nonsense, splicing, and regulatory variants, and deletions and insertions. In our study, 11 NIPBL variants were identified, among which c.6109-1G > A (P1), c.6763 + 5G > T (P2), c.7264-6T > G (P3), and c.-79-2A > G (P4) caused a disease phenotype by breaking the wild-type splice acceptor site of the NIPBL gene, which led to formation of alternative transcripts by aberrant splicing. Nucleotide transition in c.5683A > G (P5), 5615T > A (P6), and c.6722T > C (P7) led to substitution of normal residues, which is susceptible to forming abnormal protein structures. Moreover, c.6854_6855delAG (P8), c.330_331delAA (P9), c.3344G > A (P10), and c.4310T > G (P11) resulted in a premature stop codon. Except for the variant in P8, the other 10 variants appear to be de novo variants in the patients because they were absent in their parents. Variants in SMC1A residing at Xp11.22 account for approximately 5% of individuals19. P12 had a missense variant [p. (Cys781Phe)] in exon 15 of the SMC1A gene. And sequencing results showed that his mother carried the same variant, while the mother had no special phenotype. A missense variant was identified in P13 [p. (Arg363Ile)] and this was novel. Variants in RAD21 (8q24.11) and HDAC8 (Xq13.1) have been described in only a few patients. P14 had a shift frame deletion secondary to a variant of c.1553_1554delAG in exon 12 of the RAD21 gene, which led to a premature stop codon. A novel splicing variant of HDAC8 (c.628 + 1G > C) was identified in P15. Studies that have reported genotype–phenotype correlations in CdLS have described variability in clinical characteristics within and between variants. Patients with NIPBL variants are likely to present with more severe clinical features and to have more impaired cognitive function than those with other causal variants20. In our study, P13 with an SMC1A variant, P14 with an RAD21 variant, and P15 with an HDAC8 variant had non-typical facial features and mild phenotype. However, compared with the previously reported patients, P12 who had an SMC1A variant had more severe phenotype, including CHD, cleft palate and typical facial features. Therefore, the phenotype varies even for unrelated patients with the same variant, suggesting other genetic or environmental modifying factors. Furthermore, a truncated and presumably nonfunctional NIPBL protein caused by variants (nonsense, splice site, and frame shift variants) is usually associated with a more severe cognitive and structural phenotype than missense variants. However, missense variants associated with the HEAT domain cause severe phenotype5. In our study, P7 who had an NIPBL missense variant had a severe phenotype with oligodactyly, severe developmental delay, and growth retardation. This finding supports the notion that variants affecting the HEAT domain play a critical role in protein function. The patients with a non classical CdLS phenotype in this cohort (P14, P15) mainly presented with growth and developmental delay, 5th finger clinodactyly and short 5th finger and the molecular testing was needed to confirm the diagnosis. The extensive phenotypic and genetic heterogeneity of cohesinopathies difficults the diagnosis. Growth retardation and intellectual disability might be the main clinical manifestations in patients with mild facial phenotype. At present, clinical interventions for patients with CdLS are mainly symptomatic treatment. Additionally, rehabilitation training appears to be a good option for improving motor development. A previous report indicated that GH therapy may be an effective method to improve the height of patients21. However, the benefits of increased growth by GH supplementation should be weighed against the burden of daily subcutaneous injections and the lack of a positive impact of an increased adult height on the quality of life for most individuals with CdLS, as indicated in Kline AD et al. 20182. Thus, GH therapy and growth curves require further investigation in the future. Conclusion We analyzed 15 Chinese cases of CdLS secondary to NIPBL, SMC1A, RAD21, or HDAC8 variants, and among them, 11 were novel. Variants in the NIPBL gene were the most common cause in our cohort. Furthermore, presentations vary in children with CdLS. Clinical manifestations of patients in our cohort are mostly consistent with other ethnicities, but several clinical features have different frequencies. There are also some limitations of our study. This study was performed in one institute, which may have created a selection bias. Future research should expand the survey sample. And caution needs to be considered while interpreting the results, even though the results will be useful to explore the spectrum of CdLS, functional significance of the identified variants is needed. Supplementary information Supplementary Information. Abbreviations ACMGAmerican College of Medical Genetics and Genomics ASDAtrial septal defect CA-PAFCoronary-pulmonary artery fistula CdLSCornelia de Lange syndrome CHDCongenital heart disease GHGrowth hormone HGMDHuman gene mutation database HPOHuman phenotype ontology NGSTargeted next-generation sequencing PDAPatent ductus arteriosus PFOPatent foramen ovale PSPulmonic stenosis SDStandard deviation VSDVentricular septal defect Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Qun Li and Guoying Chang. Supplementary information is available for this paper at 10.1038/s41598-020-78205-5. Acknowledgements We are grateful to the patients and their families for participating in this study. This study was support by the National Natural Science Foundation of China (Grant No. 81900722) and Jin Lei Pediatric Endocrinology Growth Research Fund for Young Physicians (PEGRF) (No. PEGRF201809007). Author contributions Q.L., G.Y.C., J.W., and X.M.W. conceptualized and designed the study. Q.L. and G.Y.C. drafted the initial manuscript. L.Y., J.L., X.D.H., and Y.N.S. collected data and carried out the initial analyses. Q.L., G.Q.L., and Y.F.X. extracted and analyzed the data. J.W. and X.M.W. supported and supervised the data analysis, and reviewed and revised the manuscript. All authors approved the final manuscript and take responsibility for all aspects of the work. Competing interests The authors declare no competing interests. ==== Refs References 1. Kline AD Cornelia de Lange syndrome: Clinical review, diagnostic and scoring systems, and anticipatory guidance Am. J. Med. Genet. A 2007 143 1287 1296 10.1002/ajmg.a.31757 2. Kline AD Diagnosis and management of Cornelia de Lange syndrome: First international consensus statement Nat. Rev. Genet. 2018 19 649 666 10.1038/s41576-018-0031-0 29995837 3. Mcconnell V Brown T Morrison PJ An Irish three-generation family of Cornelia de Lange syndrome displaying autosomal dominant inheritance Clin. Dysmorphol. 2003 12 241 244 10.1097/00019605-200310000-00006 14564211 4. Dorsett D Ström L The ancient and evolving roles of cohesin in gene expression and DNA repair Curr. Biol. 2012 22 R240 250 10.1016/j.cub.2012.02.046 22497943 5. Mannini L Cucco F Quarantotti V Krantz ID Musio A Mutation spectrum and genotype–phenotype correlation in Cornelia de Lange syndrome Hum. Mutat. 2013 34 1589 1596 10.1002/humu.22430 24038889 6. Hu X Proband-only medical exome sequencing as a cost-effective first-tier genetic diagnostic test for patients without prior molecular tests and clinical diagnosis in a developing country: The China experience Genet. Med. 2018 20 1045 1053 10.1038/gim.2017.195 29095814 7. Richards S ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Genet. Med. 2015 17 405 424 10.1038/gim.2015.30 25741868 8. Biesecker LG Harrison SM ClinGen Sequence Variant Interpretation Working Group. The ACMG/AMP reputable source criteria for the interpretation of sequence variants Genet. Med. 2018 20 1687 1688 10.1038/gim.2018.42 29543229 9. Abou Tayoun AN ClinGen Sequence Variant Interpretation Working Group. Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion Hum. Mutat. 2018 39 1517 1524 10.1002/humu.23626 30192042 10. Liu J SMC1A expression and mechanism of pathogenicity in probands with X-Linked Cornelia de Lange syndrome Hum. Mutat. 2009 30 1535 1542 10.1002/humu.21095 19701948 11. Oliveira J Development of NIPBL locus-specific database using LOVD: From novel mutations to further genotype–phenotype correlations in Cornelia de Lange Syndrome Hum. Mutat. 2010 31 1216 1222 10.1002/humu.21352 20824775 12. National Center for Biotechnology Information. ClinVar; [VCV000159225.1], https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000159225.1. Accessed 2 Sep 2019. 13. Selicorni A Clinical score of 62 Italian patients with Cornelia de Lange syndrome and correlations with the presence and type of NIPBL mutation Clin. Genet. 2007 72 98 108 10.1111/j.1399-0004.2007.00832.x 17661813 14. Dowsett L Cornelia de Lange syndrome in diverse populations Am. J. Med. Genet. A 2019 179 150 158 10.1002/ajmg.a.61033 30614194 15. Rohatgi S Facial diagnosis of mild and variant CdLS: Insights from a dysmorphologist survey Am. J. Med. Genet. A 2010 152 1641 1653 10.1002/ajmg.a.33441 16. Parenti I Expanding the clinical spectrum of the ‘HDAC8-phenotype’—implications for molecular diagnostics, counseling and risk prediction Clin. Genet. 2016 89 564 573 10.1111/cge.12717 26671848 17. Chatfield KC Congenital heart disease in Cornelia de Lange syndrome: phenotype and genotype analysis Am J Med Genet A 2012 158 2499 2505 10.1002/ajmg.a.35582 18. Kline AD Natural history of aging in Cornelia de Lange syndrome Am. J. Med. Genet. C Semin. Med. Genet. 2007 145 248 260 10.1002/ajmg.c.30137 19. Huisman S Phenotypes and genotypes in individuals with SMC1A variants Am. J. Med. Genet. A 2017 173 2108 2125 10.1002/ajmg.a.38279 28548707 20. Boyle MI Jespersgaard C Brøndum-Nielsen K Bisgaard AM Tümer Z Cornelia de Lange syndrome Clin. Genet. 2015 88 1 12 10.1111/cge.12499 25209348 21. De Graaf M Successful Growth Hormone Therapy in Cornelia de Lange Syndrome J. Clin. Res. Pediatr. Endocrinol. 2017 9 366 370 10.4274/jcrpe.4349 28588001